Article: Deltagen Enters Into Gene Function Database and Target Validation Agreements with Glaxo Wellcome.

- First Information Set of Data Points for Targeted Genes Has Been Delivered -

MENLO PARK, Calif., Sept. 6 /PRNewswire/ --

Deltagen, Inc. (Nasdaq: DGEN) today announced that it entered into two agreements with Glaxo Wellcome involving Deltagen's DeltaBase(TM) gene function database and Deltagen's DeltaSelect(TM) target validation program. The first installment of the DeltaBase database has been delivered to Glaxo Wellcome, containing gene function information for potential new drug targets.

Glaxo Wellcome is the first subscriber to Deltagen's DeltaBase database for mammalian gene function. Glaxo Wellcome will have non-exclusive access to in ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!